Conventional versus Doxorubicin-eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma

Sacco, Rodolfo; Bargellini, Irene; Bertini, Marco; Bozzi, Elena; Romano, Antonio; Petruzzi, P; Tumino, E.; Ginanni, Barbara; Federici, Graziana; Cioni, Roberto; Metrangolo, S.; Bertoni, Michele; Bresci, G.; Parisi, Giuseppe Fabio; Altomare, Emanuele; Capria, A; Bartolozzi, Carlo

doi:10.1016/j.jvir.2011.07.002

Cited by 215 publications

(197 citation statements)

References 24 publications

Supporting

Mentioning

185

Contrasting

Unclassified

Order By: Relevance

“…Despite reports suggested that there was no significant difference in terms of the safety profile, tumor response, tumor recurrence and overall survival rate for DEB as compared to TACE in non-transplant patients (57,59), DEB was shown to have lower tumor recurrence rate after LT and was identified as an independent predictor of recurrence-free survival in the multivariate analysis (60). Further study should be carried out to confirm the superiority of this technique.…”

Section: Doxorubicin Eluting Bead (Deb) Transarterial Chemoembolizatimentioning

confidence: 95%

Bridging and downstaging therapy in patients suffering from hepatocellular carcinoma waiting on the list of liver transplantation

She¹,

Cheung²

2016

Transl. Gastroenterol. Hepatol.

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a common primary malignancy worldwide especially in the patients with the background of chronic liver disease. Liver transplantation (LT) is the only curative treatment effective for both malignancy as well as the cirrhosis and portal hypertension. Unfortunately, living donor is not always possible and the deceased graft is scarce. Neoadjuvant therapies, therefore, have been developed as a downstaging treatment to try to downstage the tumor within the transplant criteria, or as a bridging therapy to control the tumor growth in patients while waiting in the transplant list. This paper reviewed the common modalities used as bridging and downstaging therapies for patients suffering from HCC before undergoing LT.

show abstract

Section: Doxorubicin Eluting Bead (Deb) Transarterial Chemoembolizatimentioning

confidence: 95%

Bridging and downstaging therapy in patients suffering from hepatocellular carcinoma waiting on the list of liver transplantation

She¹,

Cheung²

2016

Transl. Gastroenterol. Hepatol.

View full text Add to dashboard Cite

show abstract

“…None of those trials demonstrated a difference in survival, but patients treated with drug-eluting bead tace consistently experienced fewer adverse events [69][70][71][72] .…”

Section: Summary Of Evidencementioning

confidence: 99%

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016

Bossé

Ahmad

et al. 2016

Current Oncology

View full text Add to dashboard Cite

The annual Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016 was held in Montreal, Quebec, 5-7 February. Experts in radiation oncology, medical oncology, surgical oncology, and infectious diseases involved in the management of patients with gastrointestinal malignancies participated in presentations and discussion sessions for the purpose of developing the recommendations presented here. This consensus statement addresses multiple topics:■ Follow-up and survivorship of patients with resected colorectal cancer ■ Indications for liver metastasectomy ■ Treatment of oligometastases by stereotactic body radiation therapy ■ Treatment of borderline resectable and unresectable pancreatic cancer ■ Transarterial chemoembolization in hepatocellular carcinoma ■ Infectious complications of antineoplastic agents

show abstract

“…It has been demonstrated to have a lower toxicity profile compared to cTACE [79] . However, studies so far failed to prove its ability to consistently prolong survival [79][80][81][82][83][84] . Moreover, as a relatively new agent, only a paucity of studies has looked at its effect on high-burden HCC, particularly those with portal vein invasion.…”

Section: Transarterial Chemoembolizationmentioning

confidence: 99%

Treatment of high-burden hepatocellular carcinoma: an oncologist perspective

Chan¹,

Chan²

2018

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is recognized as a major global healthcare burden. Although there have been tremendous improvements in cancer screening and treatment, HCC mortality rate remains high. Many patients with HCC present late to medical attention and thus are not candidates for curative treatment. They typically have high tumor burden at presentation showing heterogeneity in anatomical factors and biochemical profile. Despite the relatively poor prognosis for these patients, significant improvements can still be made in survival if the optimal treatment modality is chosen. Currently, there is no international consensus on how to manage this group of heterogeneous, high-burden HCC. In this article, we will address this question by reviewing the latest available evidences. Our definition of "high-burden HCC" will be based on three factors: size, number of tumors and the presence of macrovascular invasion. The different treatment modalities, namely surgery, intra-arterial therapy, radiotherapy and systemic therapy, and their respective supportive evidences, will be discussed. In the end, we will summarize with our views on the future direction of research priorities for the management of high-burden HCC.

show abstract

Conventional versus Doxorubicin-eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma

Cited by 215 publications

References 24 publications

Bridging and downstaging therapy in patients suffering from hepatocellular carcinoma waiting on the list of liver transplantation

Bridging and downstaging therapy in patients suffering from hepatocellular carcinoma waiting on the list of liver transplantation

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016

Treatment of high-burden hepatocellular carcinoma: an oncologist perspective

Contact Info

Product

Resources

About